Beyondspring (BYSI) Gets a Buy Rating from H.C. Wainwright

By Carrie Williams

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Beyondspring (BYSIResearch Report), with a price target of $30.00. The company’s shares closed last Monday at $12.82.

According to TipRanks.com, Pantginis is a 1-star analyst with an average return of -2.8% and a 30.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Beyondspring with a $29.67 average price target, a 138.3% upside from current levels. In a report issued on March 18, William Blair also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Beyondspring’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $9.37 million. In comparison, last year the company had a GAAP net loss of $14.93 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.